DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RELISTOR

« Back to Dashboard

Clinical Trials for Relistor

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00804141	Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation	Completed	Pfizer	Phase 3	2008-12-01	This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period.
NCT00804141	Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation	Completed	Valeant Pharmaceuticals International, Inc.	Phase 3	2008-12-01	This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period.
NCT00949377	Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?	Withdrawn	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4	2009-09-01	The investigators want to prove that people WITHOUT advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since the FDA has only approved MNTX for advanced cancer patients, the investigators' research is investigating how MNTX can work for NON-cancer patients. This research is being conducted to prove that MNTX can work for non-cancer patients with opioid related constipation.

Clinical Trial Conditions for Relistor

Condition Name

Condition Name for Relistor
Intervention	Trials
Constipation	4
Pharyngeal Dysfunction	2
Constipation Drug Induced	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Relistor
Intervention	Trials
Constipation	7
Coronary Artery Disease	1
Esophageal Diseases	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Relistor

Trials by Country

Trials by Country for Relistor
Location	Trials
United States	40
Canada	8
Korea, Republic of	3
Spain	2
Colombia	2

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Relistor
Location	Trials
Minnesota	2
Massachusetts	2
Florida	2
Washington	2
Pennsylvania	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Relistor

Clinical Trial Phase

Clinical Trial Phase for Relistor
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	3
Phase 2	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Relistor
Clinical Trial Phase	Trials
Completed	7
Withdrawn	2
Not yet recruiting	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Relistor

Sponsor Name

Sponsor Name for Relistor
Sponsor	Trials
Wyeth is now a wholly owned subsidiary of Pfizer	4
Region Örebro County	2
University of Vermont	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Relistor
Sponsor	Trials
Other	12
Industry	6

Export unavailable in trial.
Subscribe for complete access.